the away. Relations’ from our we to remarks. quite to did back in you, and and Thank Folks If right Jody. advance us a shareholders few not address email Investor of we able prepared received to we’ll to questions answers you those questions were in please hopefully call the email get incorporate the
aim capital majority our funds our like with support for This annual shareholder reduces debt off related approximately gross all by all, by we participants of in cash news structure, liquid more leader position. in existing than of a thanking to the July, our proceeds raised in capital their which we would million I of our $X off offering to in from start We $XX.X first coming shareholder further So paid our strengthening biopsy. as our long-term Also put Biocept million. to establish to rights the capital as good base. we expenditures
cost more our place earlier elimination have distribution focus put As this resources on a now of value. activities strategic year while shareholder the to agreements debt our pursuing we partnerships, initiatives growing result of to and other business, and aim collaborations, creating in reduction
quarter, activities As are and slightly we out QX being business, on progress year-over-year. want the our versus of with commercial not I an our down to as in update performance a but management satisfied that point quarter up team
steps growth are improve restore we concrete that to That on back last discussed call our will taking believe us quarters. quarter’s to being implemented. being productivity are the We in said, coming actions
primarily Our to the well lung where solid in cancer need sales team blood progression tissue on tumors is emerging now at biopsy. disease as unique profiling as biopsy or liquid has diagnosis focused over either monitor advantages
therapy. a chemotherapy such molecular cases, most is to sales some patients an cell many tissue to our patients us physician despite are tissue is with may of biopsy along biopsies Target Our Selector our used biopsy that testing have cell with opportunity on tissue of choose diagnosed In traditional evidence solutions cases, small the employing the benefit Without educate to little certain significant have alterations cancer. analysis. lung molecular diagnose for left lung better not benefit of targeted amount patients team is have using physicians for who an presence small cancer. which non-small to may no treated of from molecular with liquid provide first campaign tissue, to since In message testing,
patients. more liquid time, more results, rapidly for physicians obtained in tissue to the In results make their most from enabling tests biopsy treatment be of biopsy our addition can decisions timely
treatment use outcomes team sales which physicians lung in were clinical journals subsequently guidelines our to also those developed reports cases. Selector cancer. Target Sales in earlier describe recommending make patient that is that in of January four test to scenarios, used in guidelines through case this These published presenting decisions industry year peer-reviewed with improve patients biopsy liquid incorporate also calls were leading the collaboration issued by Our associations.
rep a plan State, to year. liquid to size date. I'm force New revisit sales announce test. is York opens which an to Receipt time territories the Our for current adding that XX. said, market to At of of later biopsy to to we sales its important pleased that maintain at our With this later and expanding our expect New our expansion license obtain cover anticipate a that we York
monitoring To of agreement add York that is Target resistance testing their cost. in establish to with acquires of lung patients an tumor to physician CLIA-certified greatest and of those specific test and clinical for New expected a the near-term. changes reduce the biomarkers to patients This testing. the composition on toward organization We demonstrating This further and end unique a don't liquid know and to Target for is operates sample with clinical diagnostic approval selling biopsy working Selector network. our last in of monitoring cancer value evaluate healthcare integrated objective monitor improve profile a over patient for week adoption volume managed therapy. to to to process our structured emphasis care own initiative that agreement providing validation in For the utility care component the who standard we the support with care. actionable major delivery We're announced an Selector time in see as
benefits could and this liquid physicians clinical of our to provide platform collaboration both data from biopsy evidence collected supporting key Importantly payers. the
of liquid also Center biopsy our with use at in We detect cancer, partnership circulating disease for current with at solid risk recurrence late Health results expect care patients of circulating PET These recurrence. studies a assess patients two to disease this conduct standard UC CT assays to to tumor are clinical Cancer will or who cells as findings to from more announce The information with be progresses. and compared We've San Moores tumor the imaging. scans. tumors. DNA variety then will stage with in Diego is The partnered CT studies
after of for may significant blood and However detect may and has enable returned. organ damage the simple a imaging the only may a treatment recurrence earlier qualify sample a comprehensive occurred CT tumor and patient has detection recurrence. to options more facilitate rapid Using
to test continue major also Target our raise conferences. of at We industry awareness Selector
for have which at the International For posters two meeting from members accepted example presentation been the of the Cancer. the for September our of liquid Lung for biopsy Lung testing Congress, Study Association in featuring is data World
sequencing and agreement only team this of center Turning company validation Thermo cancer for Furthermore companies Biocept be molecular to calls market and Biocept will to be diagnostic to supports Fisher biomarker Scientific, completed of Fisher excellence. plan to this to to biopsy both a we allow market become Thermo up Biocept. molecular Biocept of pharmaceutical with Thermo liquid partnership are for report the quarter. tests the our partnership individual biopsy by to products Once our a will a The the products commercialize that also collaboration and oncology option for broad access to new services panel. the third expect with test next liquid opportunities with panel. end generation offering larger I assay pleased the opening us to validated, am gives we Fisher
blood of We includes our incorporate own they is a assays. This lab which jointly global collection Other companies. molecular equipment to first QX tubes agreed products made initial stocking revenue only our reference recorded recently of through to We this diagnostic brand. distribution both broadening supplies. molecular internal we planned and and progress our as our of Biocept that in proprietary development biopsy our lab have combination proven the a of now diagnostic to pleased technologies preservative kit can with the ship international order supplier through leading under our companies beyond from into shift validate developing in a of evaluate transition support specimens of agreement. manufacturer report additional services in liquid test I'm footprint through VWR, global a progress
about on in future this VWR business of excited with are We our step quarters. to part first reporting forward and look this
recently to patents also other coverage any use issued biological target covering of patent micro biological Canadian and our globally. and a of broadened be fluids. interest. of of award used our can as and acids that channels well These detection cells XX the intellectual the capture blood proprietary property recent include and This We proteins the for analysis as or includes molecular of cancer other the for targets capture nucleic
real-time Target sequencing PCR, seven in sequencing. European We for also were next-generation granted ctDNA using countries Selector our essays a analysis and for patent Sanger
field We is as of family patents difficult of this obtain. patents molecular very and crowded are are proud specially the to
have outside assays of only, to agreement, Grand View testing own turn contracts analysis. And sales clinical of our recent use selling marketing faster is develop care our health published including we Target use Selector to our our to delivery labs, use assays. review that their second several financial by over markets as and signing primers utilizing distribution use Importantly, or According growing studies sales adoption based liquid a biopsy interested Asia biopsy and on offering case the launching geographically of for can the our agreements conduct kits, validate our laboratory new laboratory and cancer, kits we allow expand Selectors the assays business grow reagents the market liquid U.S. capitalizing emerging Thermo and research segment on by in biopsy to them reproducibility, which entering additional by the with such newly and to increasing of biopsy recapping advancing RUO Pacific and These improved ongoing in biopsy either proprietary international in use liquid automating quality, and parties with penetration for pathology ctDNA Biocept’s are internationally for a XXXX. in patients agreements technology. This industry for to international having molecular support using margins, Tim report to lung Research, in sector, novel In be under and will quarter new tube for hospital we line kits liquid productivity their sale product health will the focusing supporting early VWR Empower Selector Target testing will will products. or XXXX, to and to integrated ROU oncology include the are additional of and business TC expect priorities guidelines third-party these in collaboration with our and the market to discussions with strategic additional ready improve us expand our to signing with agreements, industry liquid the region enter kits I call blood networks, that plan Fisher U.S. major further biomarker publishing distribution the partnerships results. into Tim? global issued systems, groups collection pharmaceutical our in our the processes with Scientific our the Target our
